New Insulin Pump Cuts Odds of Overnight Hypoglycemia
Sensor device may ease patient fear of dangerously low blood sugar levels during sleep, experts say
By Steven Reinberg
SATURDAY, June 22 (HealthDay News) -- A new sensor attached to an insulin pump helps prevent dangerously low blood sugar levels in patients with type 1 diabetes while they sleep, a new study finds.
The new pump automatically stops delivering insulin when the sensor finds blood sugar levels have reached a pre-set low level, and it reduced overnight episodes of low blood sugar (hypoglycemia) by a third, the researchers report.
"After years of hoping for a way to achieve our goal of getting good blood sugar control without a lot of low blood sugar, we are finally, with this new technology, getting close to our goal," said study lead author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet in Minneapolis.
"Hypoglycemia has all of a sudden become an important topic," he said. "Now that we are able to keep blood sugar down, we are running up against hypoglycemia as being our biggest barrier to achieving the blood sugar control we want to get to prevent eye disease, kidney disease and amputations and heart disease."
The effects of hypoglycemia can range from dizziness to seizures to coma and death, according to Bergenstal. "Patients are scared to death saying, 'Am I going to go to sleep tonight and am I going to wake up tomorrow morning, or am I going to have a major problem in the night,'" he said.
This may also be another step to creating a so-called "artificial pancreas" for people with type 1 diabetes, who cannot make insulin on their own, Bergenstal added. "This is the first step that shows that the artificial pancreas can actually work," he said.
Although this device has been used in Europe, the new study is a move toward getting the device approved by the U.S. Food and Drug Administration.
The study was funded by Medtronic Inc., the maker of the device. The results of the study were published June 22 online in the New England Journal of Medicine, to coincide with a scheduled presentation at the American Diabetes Association annual meeting in Chicago.